NCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
Clinical Trials
12 trialsNCT00006023 2019-06-26
Capecitabine in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Swiss Cancer Institute
Phase 2 Completed
NCT00496587 2017-07-19
Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00042965 2016-07-14
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00124566 2016-01-18
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Eisai Inc.
Phase 2 Completed
NCT00151047 2015-01-21
Docetaxel Plus Capecitabine in Newly Diagnosed Localized or Locally Advanced Prostate Cancer
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT00523640 2014-02-11
A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma
University of Chicago
Phase 2 Terminated
NCT00058318 2012-11-02
S0312, Gemcitabine and Capecitabine in Treating Patients With Advanced Renal Cell (Kidney) Cancer
SWOG Cancer Research Network
Phase 2 Completed
NCT01182142 2010-08-24
Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma (RCC) Patients
Kidney Cancer Research Bureau
Phase 2 Completed
NCT00591188 2009-05-01
Capecitabine and Interferon-Alpha in Metastatic Renal Cell Carcinoma Patients With Failure on Interleukin-2 Based Regimens
Kidney Cancer Research Bureau
Phase 2 Completed
NCT00226980 2009-04-14
A Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma
Stanford University
Phase 2 Completed
NCT00496301 2009-01-14
SOGUG-02-06
Spanish Oncology Genito-Urinary Group
Phase 2 Completed